MCID: PRM024
MIFTS: 39

Primary Angle-Closure Glaucoma malady

Category: Eye diseases

Aliases & Classifications for Primary Angle-Closure Glaucoma

About this section

Aliases & Descriptions for Primary Angle-Closure Glaucoma:

Name: Primary Angle-Closure Glaucoma 11 50 13 68
Primary Angle Closure Glaucoma 11
 
Angle Closure Glaucoma 68

Classifications:



External Ids:

Disease Ontology11 DOID:1405
ICD1030 H40.2, H40.20
ICD9CM32 365.2, 365.20
NCIt45 C34640

Summaries for Primary Angle-Closure Glaucoma

About this section
MalaCards based summary: Primary Angle-Closure Glaucoma, also known as primary angle closure glaucoma, is related to cataract and open-angle glaucoma. An important gene associated with Primary Angle-Closure Glaucoma is MYOC (Myocilin), and among its related pathways are FGF signaling pathway and Syndecan-1-mediated signaling events. The drugs pilocarpine nitrate and pilocarpine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and endothelial, and related mouse phenotypes are no phenotypic analysis and vision/eye.

Related Diseases for Primary Angle-Closure Glaucoma

About this section

Diseases related to Primary Angle-Closure Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
idRelated DiseaseScoreTop Affiliating Genes
1cataract10.6
2open-angle glaucoma10.6
3glaucoma 1a, primary open angle10.5CYP1B1, MYOC
4familial hyperaldosteronism10.4CYP1B1, MYOC
5primary trimethylaminuria10.4CYP1B1, MYOC
6facial neuralgia10.4MFRP, OPTN
7ureteric orifice cancer10.3COL11A1, OPTN
8retinitis10.3
9chronic tympanitis10.3CYP1B1, OPTN
10malakoplakia10.3CYP1B1, MMP9
11paranasal sinus lymphoma10.3MYOC, OPTN
12myopathy of extraocular muscle10.3MYOC, OPTN
13ispd-related muscle diseases10.2MFRP, VSX2
14intervertebral disc disease10.2COL11A1, MMP9
15larsen-like syndrome10.2CYP1B1, OPTN
16ameloblastic carcinoma10.2MMP9, MTHFR
1746 xy gonadal dysgenesis10.2MYOC, OPTN
18neuropathy10.1
19neuropathy, hereditary sensory and autonomic, type vi10.1HGF, MMP9
20acute contagious conjunctivitis10.1CYP1B1, MYOC, OPTN
21glaucoma 3a, primary open angle, congenital, juvenile, or adult onset10.1CYP1B1, MYOC, OPTN
22secondary corneal edema10.1CYP1B1, MYOC, OPTN
23lactocele10.1CYP1B1, MYOC, OPTN
24cavernous hemangioma of colon10.1GSTM1, MMP9
25endotheliitis10.0
26functional diarrhea10.0MTHFR, VSX2
27retinitis pigmentosa9.9
28cornea plana9.9
29choroiditis9.9
30entropion9.9
31rubeosis iridis9.9
32ocular hypertension9.9
33refractive error9.9
34cornelia de lange syndrome 59.9CYP1B1, VSX2
35oral lichen planus9.8GSTM1, MMP9, MTHFR
36amyotrophic lateral sclerosis 129.7CYP1B1, GSTM1, MYOC, OPTN
37vertebrobasilar insufficiency9.7MMP9, MTHFR
38separation anxiety disorder9.1CYP1B1, GSTM1, MTHFR, MYOC, OPTN
39iritis6.5COL11A1, CYP1B1, GSTM1, HGF, KERA, MFRP

Comorbidity relations with Primary Angle-Closure Glaucoma via Phenotypic Disease Network (PDN):


Hypertension, Essential

Graphical network of the top 20 diseases related to Primary Angle-Closure Glaucoma:



Diseases related to primary angle-closure glaucoma

Symptoms & Phenotypes for Primary Angle-Closure Glaucoma

About this section

MGI Mouse Phenotypes related to Primary Angle-Closure Glaucoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00030128.5HGF, MTHFR, MYOC, OPTN, TXNRD2, VSX2
2MP:00053917.8CYP1B1, KERA, MFRP, MMP9, MTHFR, MYOC

Drugs & Therapeutics for Primary Angle-Closure Glaucoma

About this section

Drugs for Primary Angle-Closure Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 84)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
TravoprostapprovedPhase 4, Phase 3130157283-68-65282226
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
157283-68-6
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AC-6103
AC1NQZOS
AL-6221
AL6221
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CID5282226
D01964
DB00287
 
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
LS-173521
S1554_Selleck
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN]
Travoprostum
ZINC04474682
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
2
PilocarpineapprovedPhase 42754-71-7, 92-13-75910
Synonyms:
(+)-Pilocarpine
(3S,4R)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
(3S,4R)-3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
(3S,4R)-3-ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-((1-methyl-1H-imidazol-5-yl)methyl)-2(3H)-furanone
(3S-cis)-3-Ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
(3S-cis)-3-ethyldihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone
3-Ethyl-4-(3-methyl-3H-imidazol-4-ylmethyl)dihydrofuran-2-one
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydro-2(3H)-furanone
3-Ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one
3-ethyl-4-((1-methyl-1H-imidazol-5-yl)methyl)dihydro-2(3H)-furanone
3-ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
54-71-7
91484-73-0
92-13-7
AC1L1J0W
AC1L1LEF
AC1Q6MOP
AI3-50523
AR-1F3128
Adsorbocarpine
Almocarpine
Amistura P
BIDD:GT0217
BPBio1_000548
BRD-K85090592-008-05-2
BSPBio_000498
BSPBio_002191
C07474
CHEBI:39460
CHEBI:8207
CHEMBL550
CID4819
CID5910
D00525
DB01085
DivK1c_000358
EINECS 202-128-4
Epicar
HMS2089K17
HSDB 3163
IDI1_000358
Imidazole-5-butyric acid, alpha-ethyl-beta-(hydroxymethyl)-1-methyl-, gamma-lactone
Isopto carpine
Isoptocarpine
KBio1_000358
KBio2_001587
KBio2_004155
KBio2_006723
KBio3_001691
KBioGR_000956
KBioSS_001587
L001181
LS-187208
LS-7661
Lopac0_000950
Lopac0_000960
Mi-Pilo
Minims Pilocarpine
Miocarpine
MolPort-002-512-506
NCGC00023339-03
 
NCGC00023339-06
NCGC00023339-07
NCGC00023339-08
NCGC00023339-09
NCGC00023339-12
NCGC00023339-13
NCI60_004403
NINDS_000358
NSC5746
Ocu-Carpine
Ocusert
Ocusert P 20
Ocusert Pilo-40
Ocusert pilo
Ocusert pilo-20
Ocusert pilo-20 (TN)
P.V. Carpine Liquifilm
Pilagan
Pilocarpin
Pilocarpine
Pilocarpine (JAN/USP)
Pilocarpine HCl
Pilocarpine Mononitrate, (3S-cis)-Isomer
Pilocarpine [USAN:BAN:JAN]
Pilocarpine chloride
Pilocarpine hydrochloride
Pilocarpine monohydrochloride
Pilocarpine muriate
Pilocarpine nitrate
Pilocarpine, Monohydrochloride, (3S-cis)-Isomer
Pilocarpol
Pilokarpin
Pilokarpin monohydrochloride
Pilokarpol
Piloptic-1
Piloptic-1/2
Piloptic-2
Piloptic-3
Piloptic-4
Piloptic-6
Pilostat
Prestwick0_000449
Prestwick1_000449
Prestwick2_000449
Prestwick3_000449
SDCCGMLS-0003164.P005
SPBio_001287
SPBio_002437
STOCK1N-18408
Salagen
Spectrum2_001284
Spectrum3_000546
Spectrum4_000478
Spectrum5_001379
Spectrum_001107
Spersacarpine
Spersacarpine hydrochloride
Syncarpine
Tocris-0694
UNII-01MI4Q9DI3
ZINC00075008
beta-Pilocarpine hydrochloride
isopilocarpine
nchembio.78-comp9
pilocarpine
3
TopiramateapprovedPhase 424797240-79-45284627
Synonyms:
-D-fructopyranose deriv.
.beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate (9CI)
2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-36-D-fructo-pyranose sulfamate
2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
2,3:4,5-Di- O -isopropylidene-(beta)-D-fructopyranose sulfamate
2,3:4,5-Di-O-isopropylidene-beta-D-fructopyranose sulfamate
5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.
97240-79-4
AKOS000424547
BIDD:GT0854
BIDD:PXR0127
BRN 5988957
BSPBio_002306
C052342
C07502
C12H21NO8S
CBChromo1_000352
CHEBI:129573
CHEMBL220492
CID5284627
CPD000466325
Cilag brand of topiramate
D00537
DB00273
Epitoma
Epitomax
HMS1922H06
HMS2051L09
HMS2093D20
HSDB 7531
Janssen brand of topiramate
KS-1122
KW-6485
LS-187392
LS-69764
MLS000759431
MLS001424070
McN 4853
McN-4853
MolPort-001-615-062
MolPort-002-885-869
NCGC00178714-01
 
Ortho brand of topiramate
RWJ 17021
RWJ-17021
RWJ-17021-000
S1438_Selleck
SAM001246601
SMR000466325
SPBio_000995
SPECTRUM1505801
STOCK1N-71037
Spectrum2_001128
T0575_SIGMA
TL8006021
TOR
TPM
Tipiramate
Tipiramate [French]
Tipiramato
Tipiramato [Spanish]
Topamac
Topamax
Topamax (TN)
Topamax Sprinkle
Topamax, Topiramate
Topimax
Topina
Topiramate
Topiramate (JAN/USAN/INN)
Topiramate (TPM)
Topiramate / Placebo
Topiramate [USAN:BAN:INN]
Topiramato
Topiramato [INN-Spanish]
Topiramatum
Topiramatum [INN-Latin]
Topiramic acid
Topomax
UNII-0H73WJJ391
USL-255
[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate
beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, 1-sulfamate
topiramate
topiramate tablet
topiramatum [Latin]
4
Acetazolamideapproved, vet_approvedPhase 47559-66-51986
Synonyms:
1424-27-7 (mono-hydrochloride salt)
1yda
1ydb
1ydd
1zsb
2-acetylamino-1,3,4-Thiadiazole-5-sulfonamide
2h4n
3czv
4-Diamox
5-ACETAMIDO-1,3,4-thiadiazole-2-sulfonamide
5-acetylamino-1,3,4-Thiadiazole-2-sulfonamide
5661-25-6
59-66-5
8017-69-4
A 6011
A6011_SIAL
A6011_SIGMA
AB00051906
AC-12779
AC1L1CO5
AI3-52458
AKOS000715163
Acetadiazol
Acetamidothiadiazolesulfonamide
Acetamox
Acetazolam
Acetazolamid
Acetazolamida
Acetazolamida [INN-Spanish]
Acetazolamide (AAZ)
Acetazolamide (JP15/USP/INN)
Acetazolamide Apotex Brand
Acetazolamide Chiesi Brand
Acetazolamide Dioptic Brand
Acetazolamide Grin Brand
Acetazolamide ICN Brand
Acetazolamide Jumer Brand
Acetazolamide Llorens Brand
Acetazolamide Medphano Brand
Acetazolamide Novopharm Brand
Acetazolamide Orion Brand
Acetazolamide Sodium
Acetazolamide Sodium, (Sterile)
Acetazolamide Wassermann Brand
Acetazolamide [INN:BAN:JAN]
Acetazolamide, Monosodium Salt
Acetazolamidum
Acetazolamidum [INN-Latin]
Acetazolamine
Acetazoleamide
Acetozalamide
Acétazolamide
Ak Zol
Ak-Zol
AkZol
Apo Acetazolamide
Apo-Acetazolamide
ApoAcetazolamide
Apotex Brand of Acetazolamide
Atenezol
BAS 01585728
BIDD:GT0643
BPBio1_000007
BSPBio_000005
BSPBio_001788
C06805
C4H6N4O3S2
CAS-59-66-5
CCRIS 5811
CHEBI:27690
CHEMBL20
CID1986
CPD0-1626
CPD000058394
Carbonic Anhydrase Inhibitor 6063
Carbonic Anhydrase Inhibitor No. 6063
Carbonic anhydrase inhibitor 6063
Chiesi Brand of Acetazolamide
Ciba Vision Brand of Acetazolamide
Cidamex
D000086
D00218
DB00819
Dazamide
Defiltran
Dehydratin
Diacarb
Diakarb
Diamox
Diamox (TN)
Diamox Sequels
Didoc
Diluran
 
Dioptic Brand of Acetazolamide
Diuramid
Diuramide
Diureticum-Holzinger
Diureticum-holzinger
Diuriwas
Diutazol
DivK1c_000017
Donmox
Duiramid
EINECS 200-440-5
EU-0100039
Edemox
Eumicton
Fonurit
Glauconox
Glaumox
Glaupax
Glupax
Grin Brand of Acetazolamide
HMS1568A07
HMS1920A05
HMS2091G05
HMS500A19
HSDB 3002
Huma Zolamide
Huma-Zolamide
HumaZolamide
I09-0425
ICN Brand of Acetazolamide
IDI1_000017
Jumer Brand of Acetazolamide
KBio1_000017
KBio2_000358
KBio2_002926
KBio2_005494
KBio3_001288
KBioGR_000558
KBioSS_000358
LS-10227
Llorens Brand of Acetazolamide
Lopac-A-6011
Lopac0_000039
MLS000028435
MLS001148438
Medphano Brand of Acetazolamide
MolPort-001-783-578
Monosodium Salt Acetazolamide
N-[5-(Aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide
N-[5-(Aminosulfonyl)-1,3,5-thiadiazol-2-yl]acetamide
NCGC00015074-01
NCGC00015074-02
NCGC00015074-03
NCGC00015074-06
NCGC00015074-11
NCGC00023455-03
NCGC00023455-04
NCGC00023455-05
NCGC00023455-06
NCGC00023455-07
NINDS_000017
NSC 145177
NSC145177
Natrionex
Nephramid
Nephramide
Novopharm Brand of Acetazolamide
Orion Brand of Acetazolamide
Phonurit
Prestwick0_000003
Prestwick1_000003
Prestwick2_000003
Prestwick3_000003
Prestwick_4
SAM002554883
SBB056640
SK-acetazolamide
SMR000058394
SPBio_000004
SPBio_001926
SPECTRUM1500102
Sk-Acetazolamide
Spectrum2_000082
Spectrum3_000284
Spectrum4_000139
Spectrum5_000738
Spectrum_000018
Storz Brand of Acetazolamide Preparation
Storzolamide
UNII-O3FX965V0I
Vetamox
WLN: T5NN DSJ CSZW EMV1
Wassermann Brand of Acetazolamide
Wyeth Brand of Acetazolamide Preparation
acetazolamide
5
Latanoprostapproved, investigationalPhase 4, Phase 3197130209-82-45282380, 5311221
Synonyms:
130209-82-4
AC1NSK8Q
AR-202
Ambap130209-82-4
CHEBI:6384
CHEMBL1051
CID5311221
CPD000466354
Catioprost
D00356
HMS2051H11
HMS2089J17
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Jsp001835
L1167_SIGMA
Latanoprost
Latanoprost (JAN/USAN/INN)
Latanoprostum
MLS000759468
MLS001424106
 
MolPort-003-942-862
Nova-21027
PHXA-41
PhXA 41
PhXA34 [as 15(R,S)-isomer]
PhXA41
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
S1254_Selleck
SAM001246671
SMR000466354
TL8000716
XA-41
XA41
Xalatan
Xalatan (TN)
Xalatan Fixed Flow Device
ZINC12468792
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
latanoprost
latanoprost free acid
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
6
TimololapprovedPhase 4, Phase 325226839-75-833624, 5478
Synonyms:
(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-timolol
131628-37-0
194288-09-0
26839-75-8
26921-17-5 (maleate (1:1) salt)
AB00513729
AC1L1PYN
AC1Q59QM
Apo-Timol
Apo-Timop
Aquanil
BIDD:GT0073
BPBio1_001008
BRD-K08806317-050-03-6
BSPBio_000916
Betim
Betimol
Betimol (TN)
Blocadren
C07141
C13H24N4O3S
CAS-26921-17-5
CHEBI:9599
CHEMBL499
CID33624
CPD001456519
D08600
DB00373
DB08625
EINECS 248-032-6
HMS2089I11
HSDB 6533
Istalol
L-714,465
LS-122231
Lopac-T-6394
Lopac0_001189
MK-950
NCGC00016038-01
 
NCGC00016038-02
NCGC00016798-01
NCGC00016798-07
NCGC00022033-02
NCGC00022033-04
NCGC00022033-05
Novo-Timol
Nu-Timolol
Oprea1_640981
Optimol
Phoxal-timolol
Prestwick0_000948
Prestwick1_000948
Prestwick2_000948
Prestwick3_000948
Proflax
S(-)-Timolol maleate
S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
SAM002564238
SPBio_003075
ST072193
TIM
Temserin
Tenopt
Tim-AK
Timacar
Timacor
Timolol
Timolol (INN)
Timolol (TN)
Timolol GFS
Timolol Maleate, (1:1) Salt
Timolol [USAN]
Timolol anhydrous
Timolol maleate
Timololo
Timololum
Timololum [INN-Latin]
Timopic
Timoptic
Timoptic OcuDose
Timoptic in Ocudose
Timoptic-XE
Timoptol
Tocris-0649
UNII-817W3C6175
timolol
7
BrinzolamideapprovedPhase 4, Phase 360138890-62-768844
Synonyms:
(+)-4-ETHYLAMINO-3,4-DIHYDRO-2-(METHOXY)PROPYL-2H-THIENO[3,2-E]-1,2-THIAZINE-6-SULFONAMIDE-1,1-DIOXIDE
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-1,1-dioxo-3,4-dihydrothieno[3,2-e]thiazine-6-sulfonamide
(4R)-4-(ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide
(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide 1,1-dioxide
(R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno(3,2-e)-1,2-thiazine-6-sulfonamide
138890-62-7
2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide,4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-,1,1-dioxide,R
3znc
AB00513824
AC-5277
AC1L2AKA
AC1Q6UVB
AKOS005145708
AL 4862
AL-4862
AL04862
Alcon brand of brinzolamide
Allphar brand of brinzolamide
Azopt
Azopt (TN)
BIDD:GT0039
BPBio1_000539
BRD-K74913225-001-03-3
BSPBio_000489
BZ1
 
Birnzolamide
Brinzolamide
Brinzolamide (BRZ)
Brinzolamide (JAN/USP/INN)
Brinzolamide [USAN]
C07760
C111827
C12H21N3O5S3
CHEBI:3176
CHEMBL220491
CID68844
D00652
DB01194
FT-0082471
HMS1569I11
I09-0605
LS-173036
MLS002153787
MolPort-005-940-291
Prestwick0_000365
Prestwick1_000365
Prestwick2_000365
Prestwick3_000365
SMR001233169
SPBio_002410
UNII-9451Z89515
8
Maleic acidexperimentalPhase 4293110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
9Adrenergic AgonistsPhase 4, Phase 32877
10Adrenergic alpha-2 Receptor AgonistsPhase 4, Phase 3911
11Adrenergic AgentsPhase 4, Phase 35140
12Anti-Arrhythmia AgentsPhase 4, Phase 32969
13AnticonvulsantsPhase 42620
14Brimonidine TartratePhase 4, Phase 312270359-46-5
15Ophthalmic SolutionsPhase 4, Phase 3, Phase 21092
16Adrenergic beta-AntagonistsPhase 4, Phase 31154
17Adrenergic AntagonistsPhase 4, Phase 31535
18Adrenergic alpha-AgonistsPhase 4, Phase 31625
19Antihypertensive AgentsPhase 4, Phase 3, Phase 24095
20Natriuretic AgentsPhase 41645
21diureticsPhase 41372
22Neuroprotective AgentsPhase 4, Phase 3, Phase 21672
23Anti-Obesity AgentsPhase 4411
24Protective AgentsPhase 4, Phase 3, Phase 27190
25Neurotransmitter AgentsPhase 4, Phase 317734
26Carbonic Anhydrase InhibitorsPhase 4179
27Pharmaceutical SolutionsPhase 4, Phase 2, Phase 37793
28Autonomic AgentsPhase 4, Phase 29774
29Peripheral Nervous System AgentsPhase 4, Phase 222776
30Cholinergic AgentsPhase 43846
31Brimonidine Tartrate, Timolol Maleate Drug CombinationPhase 424
32
Glatiramer Acetateapproved, investigationalPhase 393147245-92-93081884
Synonyms:
(2S)-2,6-diaminohexanoic acid
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-aminopentanedioic acid
(2S)-2-aminopropanoic acid
147245-92-9
AC1MIXQC
Aventis brand of copolymer 1
C089995
CID3081884
COP-1
Copaxone
Copolymer 1
 
Copolymer-1
Copoylmer 1
Glatiramer acetate
Glatiramer acetate [USAN]
L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt)
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)
LS-186971
LS-71889
TV 5010
TV-5010
TV5010
Teva brand of copolymer 1
UNII-5M691HL4BO
acetic acid
33
Triamcinoloneapproved, vet_approvedPhase 2, Phase 3482124-94-731307
Synonyms:
(8S,9R,10S,11S,13S,14S,16R,17S)-9-fluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
11-beta,16-alpha,17-alpha,21-Tetrahydroxy-9-alpha-fluoro-1,4-pregnadiene-3,20-dione
11.Beta.,16.alpha.,17.alpha., 21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11.beta.,16.alpha.,17.alpha.,21-Tetrahydroxy-9.alpha.-fluoro-1,4-pregnadiene-3,20-dione
11β,16α,17α,21-tetrahydroxy-9α-fluoro-1,4-pregnadiene-3,20-dione
124-94-7
4-08-00-03629 (Beilstein Handbook Reference)
83474-03-7
9-Fluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-11-beta,16-alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9-alpha-Fluoro-16-alpha-hydroxyprednisolone
9-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.Alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahy
9.Alpha.-Fluoro-11.beta.,16.alpha.,17.alpha., 21-tetrahydroxypregna-1,4-diene-3,20-d
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-11.beta.,16.alpha.,17.alpha.,21-tetrahydroxypregna-1,4-diene-3,20-dione
9.alpha.-Fluoro-16.alpha.-hydroxyprednisolone
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxy-1,4-pregnadiene-3,20-dione
9alpha-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9alpha-Fluoro-16alpha-hydroxyprednisolone
9α-fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-11β,16α,17α,21-tetrahydroxypregna-1,4-diene-3,20-dione
9α-fluoro-16α-hydroxyprednisolone
AC-2072
AC1L1LDH
AC1Q5HJC
Adcortyl
Aristocort
Aristocort A
Aristocort Tablets
Aristogel
Aristospan
Azmacort
BPBio1_000154
BRD-K77554836-001-03-3
BRN 2341955
BSPBio_000140
Bio-0662
C21H27FO6
CHEMBL1451
CID31307
CL 19823
Celeste
Cinolone
Cinolone-T
D00385
D014221
DB00620
Delphicort
EINECS 204-718-7
EU-0101179
Fluoxiprednisolone
Fluoxyprednisolone
Flutex
Fougera
HMS1568G22
HMS2090D12
HSDB 3194
Kenacort
Kenacort (TN)
Kenacort-A
Kenacort-AG
Kenacort-Ag
Kenalog
Kenalog in Orabase
Kenalog-10
Kenalog-40
Kenalog-H
LS-698
Ledercort
Lopac0_001179
 
MLS000028542
MLS001066543
MLS002695935
MolPort-002-528-981
Mycolog
NCGC00021580-03
NCGC00021580-04
NCGC00021580-05
NCGC00021580-06
NCGC00021580-07
NCI60_000750
NSC 13397
NSC13397
Nasacort
Nasacort Aq
Nasacort Hfa
Omcilon
Omicilon
Oracort
Oralone
Orion
Polcortolon
Pregna-1,4-diene-3,20-dio
Pregna-1,4-diene-3,20-dione, 9-fluoro-11,16,17,21-tetrahydroxy-, (11beta,16alpha)
Pregna-1,4-diene-3,20-dione, 9-fluoro-11beta,16alpha,17,21-tetrahydroxy- (8CI)
Prestwick0_000120
Prestwick1_000120
Prestwick2_000120
Prestwick3_000120
Prestwick_438
Rodinolone
S1933_Selleck
SK-Triamcinolone
SMP1_000300
SMR000058333
SPBio_002079
Sk-Triamcinolone
T6376_SIGMA
TRIAMCINOLONE (SEE ALSO TRIAMCINOLONE ACETONIDE (76-25-5) AND TRIAMCINOLONE DIACETATE (67-78-7))
Tiamcinolonum
Tiamcinolonum [INN-Latin]
Tri-Nasal
Triacet
Triacort
Triam-Tablinen
Triamcet
Triamcinalone
Triamcinlon
Triamcinolon
Triamcinolona
Triamcinolona [INN-Spanish]
Triamcinolone (JP15/USP/INN)
Triamcinolone [USAN:INN:BAN:JAN]
Triamcinolone acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Triamcinolonum
Triamcinolonum [INN]
Triatex
Tricortale
Triderm
Trilone
Tristoject
Trymex
UNII-1ZK20VI6TY
Vetalog
Volon
Volon A
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ GQ
ZINC03882036
droxypregna-1,4-diene-3,20-dione
ione
nchembio.2007.53-comp7
triamcinolone
34MitomycinsPhase 3233
35Antibiotics, AntitubercularPhase 36972
36Nucleic Acid Synthesis InhibitorsPhase 34855
37Anti-Bacterial AgentsPhase 310884
38TetrahydrozolinePhase 3593
39Alkylating AgentsPhase 34694
40Antirheumatic AgentsPhase 310627
41Adjuvants, ImmunologicPhase 32484
42Immunosuppressive AgentsPhase 3, Phase 212770
43triamcinolone acetonidePhase 2, Phase 3482
44Triamcinolone hexacetonidePhase 2, Phase 3482
45Triamcinolone diacetatePhase 2, Phase 3482
46Anti-Inflammatory AgentsPhase 2, Phase 310355
47Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 2, Phase 312767
48glucocorticoidsPhase 2, Phase 34920
49Hormone AntagonistsPhase 2, Phase 312778
50HormonesPhase 2, Phase 313979

Interventional clinical trials:

(show top 50)    (show all 53)
idNameStatusNCT IDPhase
1Relationship Between Topiramate Use and Ocular Angle StatusUnknown statusNCT00153699Phase 4
2Combined Phacotube vs Phacotrabeculectomy:A Randomized Controlled TrialUnknown statusNCT00273221Phase 4
3ALPI vs Medical Therapy Effects on Optic Nerve Structure & FunctionUnknown statusNCT00485238Phase 4
4Travoprost 0.004% Versus Pilocarpine 1% in Patients With Chronic Angle Closure Glaucoma (CACG)CompletedNCT00762645Phase 4
5Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®CompletedNCT00799682Phase 4
6Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma PatientsTerminatedNCT01151904Phase 4
7Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)TerminatedNCT00758342Phase 4
8Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure GlaucomaUnknown statusNCT01004900Phase 3
9Argon Laser Peripheral Iridoplasty for Primary Angle Closure GlaucomaUnknown statusNCT00980473Phase 3
10Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle ClosureUnknown statusNCT01936129Phase 3
11Oculusgen (Ologen) Glaucoma MMC Control in EstoniaUnknown statusNCT00524758Phase 3
12A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure GlaucomaCompletedNCT00051181Phase 3
13Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?CompletedNCT00853905Phase 2, Phase 3
14Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)CompletedNCT01965106Phase 2
15A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure GlaucomaActive, not recruitingNCT02152774Phase 2
16Use of Topical Euphrasia, a Homeopathic Remedy in OphthalmologyEnrolling by invitationNCT02416128Phase 2
17Lucentis for New Onset Neovascular GlaucomaWithdrawnNCT00727038Phase 1, Phase 2
18Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over StudyUnknown statusNCT00567788
19Angle Closure (Glaucoma) in CaucasiansUnknown statusNCT02054403
20Optical Coherence Tomography Quantitative Analysis of Changes in Anterior Chamber After Laser Peripheral LridotomyUnknown statusNCT02279472
21The Genetic Study of Primary Angle-Closure GlaucomaUnknown statusNCT00155857
22Prevalence of Angle Closure in Caucasian HyperopesUnknown statusNCT00823706
23Protective Effect of Phenytoin on GlaucomaUnknown statusNCT00739154
24Intraocular Pressure Control After Anterior Segment Laser - Comparison Between 2 DrugsUnknown statusNCT01417858
25Prevalence of Glaucoma in the Israeli Arab PopulationUnknown statusNCT01546740
26Comparison of Phacotrabeculectomy and Trabeculectomy in the Treatment of Primary Angle-closure Glaucoma (PACG)CompletedNCT01298635
27Comparison of Anterior Chamber Paracentesis and Conventional Mannitol Infusion in Patients With Primary Acute Angle-closure GlaucomaCompletedNCT01266343
28Laser Iridotomy Versus Phacoemulsification in Acute Angle ClosureCompletedNCT00350428
29Primary Angle Closure Glaucoma and Aqueous DynamicsCompletedNCT00719290
30Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - ClosureCompletedNCT01923454
31Comparing Phaco/IOL Versus Phaco/IOL + Goniosynechialysis in Subjects With PACGCompletedNCT02376725
32An Open Label Study Assessing the 24-hour Intraocular Pressure Pattern in PAC and PACG Patients, Before and After Laser Peripheral IridotomyCompletedNCT01906138
33Comparison of Gonioscopy With Cirrus and VisanteCompletedNCT01895686
34Dysphotopsia Following Laser Peripheral IridotomyCompletedNCT01758237
35Short-term Outcomes of Iridoplasty for Persistent Angle Closure Despite Patent IridotomiesCompletedNCT02199158
36Water Drinking Test in Patients With Occludable AngleCompletedNCT02613533
37Prospective Evaluation of the Efficacy of Pascal Laser Iridotomy and Pascal Laser Peripheral Iridoplasty: A Pilot StudyCompletedNCT01020071
38Sequential Laser Iridotomy Using Argon and Q-Switched 532 nm Frequency Doubled Neodymium Yag Laser: A Pilot StudyCompletedNCT00452998
39Role of Polymorphisms in the IL-1 Gene ClusterCompletedNCT00346541
40Will Listening to Music Make it Easier to Take a Visual Field Test?CompletedNCT01027039
41The Effect of Ocular Massage on the Management of Elevated Intraocular Pressure After Acute Angle ClosureCompletedNCT02539758
42Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or SyndromeCompletedNCT02049333
43Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle ClosureRecruitingNCT02613013
44Comparing Nd:YAG Laser and Sequential Double Frequency YAG-Nd:YAG Laser IridotomyRecruitingNCT02474238
45Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot StudyRecruitingNCT02865473
46Advanced Glaucoma Progression StudyActive, not recruitingNCT01742819
47Clinical Study of LPI on Different Sites of IrisActive, not recruitingNCT02870504
48Clinical Study of LPI With Different Laser WavelengthsActive, not recruitingNCT02901730
49Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Primary Angle Closure GlaucomaNot yet recruitingNCT02964676
50Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral IridotomyNot yet recruitingNCT02955641

Search NIH Clinical Center for Primary Angle-Closure Glaucoma

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Primary Angle-Closure Glaucoma

About this section

Anatomical Context for Primary Angle-Closure Glaucoma

About this section

MalaCards organs/tissues related to Primary Angle-Closure Glaucoma:

36
Eye, Testes, Endothelial, Retina, Brain

Publications for Primary Angle-Closure Glaucoma

About this section

Articles related to Primary Angle-Closure Glaucoma:

(show top 50)    (show all 362)
idTitleAuthorsYear
1
Evaluation of potential risk factors for development of primary angle-closure glaucoma in Bouviers des Flandres. (28001106)
2017
2
Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation based on data from the EAGLE trial. (28087548)
2017
3
Limbus-insertion distance of superior rectus in primary angle closure glaucoma: an anterior segment OCT study. (27938955)
2016
4
Patient-Reported Vision-Related Quality-of-Life Differences between Primary Angle-Closure Glaucoma and Primary Open-Angle Glaucoma. (27690232)
2016
5
Primary angle-closure glaucoma: A retrospective interventional case series in South India. (27013823)
2016
6
Association of Matrix Metalloproteinase-9 (MMP9) Variants with Primary Angle Closure and Primary Angle Closure Glaucoma. (27272641)
2016
7
Genome-wide association study identifies five new susceptibility loci for primary angle closure glaucoma. (27064256)
2016
8
Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. (27707497)
2016
9
Factors affecting refractive outcome after cataract surgery in primary angle-closure glaucoma. (27082207)
2016
10
Argon Laser Peripheral Iridoplasty for Primary Angle-Closure Glaucoma: A Randomized Controlled Trial. (26707418)
2016
11
Trends in Acute Primary Angle-Closure Glaucoma, Peripheral Iridotomy and Cataract Surgery in Scotland, 1998-2012. (26751514)
2016
12
Primary angle closure glaucoma: What we know and what we don't know. (28039061)
2016
13
Managing Primary Angle Closure Glaucoma - The Role of Lens Extraction in this Era. (27014390)
2016
14
Selective Laser Trabeculoplasty in Primary Angle-closure Glaucoma After Laser Peripheral Iridotomy: A Case-Control Study. (26945310)
2016
15
Trabeculectomy and Combined Phacoemulsification-Trabeculectomy: Outcomes and Risk Factors for Failure in Primary Angle Closure Glaucoma. (27513900)
2016
16
Verification of a formula developed to predict the postoperative intraocular pressure after cataract surgery in primary angle-closure glaucoma. (27686500)
2016
17
Erratum. Lack of Association Between Corneal Hysteresis and Corneal Resistance Factor With Glaucoma Severity in Primary Angle Closure Glaucoma. (26943150)
2016
18
Pattern of Visual Field Loss in Primary Angle-Closure Glaucoma Across Different Severity Levels. (27423311)
2016
19
Intra-ocular pressure fluctuation after cataract surgery in primary angle-closure glaucoma eyes medically controlled after laser iridotomy. (27040022)
2016
20
Association of PLEKHA7, COL11A1 and PCMTD1-ST18 gene polymorphisms with primary angle closure glaucoma in ethnic Han Chinese from Sichuan]. (27455018)
2016
21
Factors affecting refractive outcome after cataract surgery in primary angle-closure glaucoma: methodological issues of prediction model. (27526198)
2016
22
The association between serum uric acid and glaucoma severity in primary angle closure glaucoma: a retrospective case-control study. (27926530)
2016
23
Management of Primary Angle-Closure Glaucoma. (26886121)
2016
24
Phacoemulsification versus combined phacotrabeculectomy in the treatment of primary angle-closure glaucoma with cataract: a Meta-analysis. (27162736)
2016
25
Anterior segment imaging-based subdivision of subjects with primary angle-closure glaucoma. (27935603)
2016
26
Factors affecting refractive outcome after cataract surgery in primary angle-closure glaucoma: methodological issues of prediction model - response. (27526301)
2016
27
Evaluation of Ex-PRESS implantation combined with phacoemulsification in primary angle-closure glaucoma. (27603352)
2016
28
Impact of Socioeconomic Status on the Diagnosis of Primary Open-Angle Glaucoma and Primary Angle Closure Glaucoma: A Nationwide Population-Based Study in Taiwan. (26905307)
2016
29
Re: Narayanaswamy etA al.: Argon laser peripheral iridoplasty for primary angle-closure glaucoma: a randomized controlled trial (Ophthalmology 2016;123:514-21). (27450829)
2016
30
Associations of polymorphisms of rs1015213 with primary angle closure glaucoma-recent evidence and a meta-analysis. (26379874)
2015
31
Evaluation of the Association Between Common Genetic Variants Near the ABCA1 Gene and Primary Angle Closure Glaucoma in a Han Chinese Population. (26431478)
2015
32
Anatomical effects of clear lens extraction by phacoemulsification versus trabeculectomy on anterior chamber drainage angle in primary angle-closure glaucoma (PACG) patients. (25644619)
2015
33
Swept-source optical coherence tomography assessment of iris-trabecular contact after phacoemulsification with or without goniosynechialysis in eyes with primary angle closure glaucoma. (25573150)
2015
34
A Novel KERA Mutation in a Case of Autosomal Recessive Cornea Plana With Primary Angle-Closure Glaucoma. (25967529)
2015
35
The role of lens extraction in the current management of primary angle-closure glaucoma. (25565368)
2015
36
A Possible Role for LTBP2 in the Etiology of Primary Angle Closure Glaucoma. (26425313)
2015
37
Lack of Association Between Corneal Hysteresis and Corneal Resistance Factor With Glaucoma Severity in Primary Angle Closure Glaucoma. (26517405)
2015
38
A Study on the Central Corneal Thickness of Primary Angle Closure and Primary Angle Closure Glaucoma and Its Effect on Visual Field Progression. (26065503)
2015
39
Circadian Intraocular Pressure Fluctuation and Disease Progression in Primary Angle Closure Glaucoma. (26230764)
2015
40
Guidelines for treatment of chronic primary angle-closure glaucoma. (25459683)
2015
41
Network Centrality of Resting-State fMRI in Primary Angle-Closure Glaucoma Before and After Surgery. (26506229)
2015
42
Plateau Iris in Primary Angle Closure Glaucoma: An Ultrasound Biomicroscopy Study. (25943727)
2015
43
Factors correlating with failure to control intraocular pressure in primary angle-closure glaucoma eyes with coexisting cataract treated by phacoemulsification or combined phacotrabeculectomy. (26068613)
2015
44
Plateau iris in Japanese patients with primary angle closure and primary angle closure glaucoma. (26170608)
2015
45
The genetic mechanisms of primary angle closure glaucoma. (26206529)
2015
46
Effects of Phacoemulsification Combined With Goniosynechialysis on Primary Angle-closure Glaucoma. (26066498)
2015
47
Efficacy And Safety of Surgical Treatment Options for Primary Angle Closure Glaucoma: a Meta-Analysis of Randomised Controlled Trials. (26532341)
2015
48
New findings in the diagnosis and treatment of primary angle-closure glaucoma. (26518079)
2015
49
Variants in Nebulin (NEB) Are Linked to the Development of Familial Primary Angle Closure Glaucoma in Basset Hounds. (25938837)
2015
50
The Impact of Lens Vault on Visual Acuity and Refractive Error: Implications for Management of Primary Angle-Closure Glaucoma. (25943738)
2015

Variations for Primary Angle-Closure Glaucoma

About this section

Expression for genes affiliated with Primary Angle-Closure Glaucoma

About this section
Search GEO for disease gene expression data for Primary Angle-Closure Glaucoma.

Pathways for genes affiliated with Primary Angle-Closure Glaucoma

About this section

Pathways related to Primary Angle-Closure Glaucoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6HGF, MMP9
29.6HGF, MMP9

GO Terms for genes affiliated with Primary Angle-Closure Glaucoma

About this section

Cellular components related to Primary Angle-Closure Glaucoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1proteinaceous extracellular matrixGO:00055789.1COL11A1, KERA, MMP9, MYOC

Biological processes related to Primary Angle-Closure Glaucoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1collagen fibril organizationGO:003019910.4COL11A1, CYP1B1
2endodermal cell differentiationGO:003598710.4COL11A1, MMP9
3visual perceptionGO:00076018.7COL11A1, CYP1B1, KERA, MFRP, VSX2

Sources for Primary Angle-Closure Glaucoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet